BioSpace News Archive

DENTSPLY SIRONA Inc., and Byte, a rapidly growing clear aligner company, announced that Dentsply Sirona acquired Byte in an all-cash deal for $1.04 billion.

CytoSorb now immediately commercially available throughout North America for use in COVID-19 patients, and in a total of 67 countries worldwide

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that the Company’s management will participate in virtual 1x1 investor meetings

TransEnterix, Inc. (NYSE American: TRXC) announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will present at two upcoming virtual investor conferences:

SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that the International Society for the Advancement of Spine Surgery (ISASS) published an early view of its updated Policy on MIS Sacroiliac Joint Fusion (For Chronic Sacroiliac Joint Pain) in the December 2020 issue of the International Journal of Spine Surgery (https://www.ijssurgery.com)

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointment of William C. Roberts as its Vice President, Investor Relations & Corporate Communications.

Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the company’s lead product candidate, PBGM01,

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced the U.S. Food and Drug Administration (FDA) has conditionally accepted LYPDISO™ as the proposed brand name for MAT9001, the Company’s investigational drug for treatment of cardiovascular and metabolic conditio

CIMC Enric Holdings Limited, announced that its subsidiary Zhangjiagang CIMC Sanctum Cryogenic Equipment Co., Ltd recently started R&D of liquid nitrogen biological containers for long-term cryogenic storage of vaccines, stem cells, plasma, semen, embryos and various tissues and organs for the needs of the biomedical industry.

Both will help NexImmune advance current early-stage clinical trials and will guide Company’s translational efforts to develop new immunotherapy products